| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Mereo BioPharma Group plc (NASDAQ: MREO)
MREO Technical Analysis
5
| As on 29th Dec 2025 MREO STOCK Price closed @ 0.29 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.43 & Strong Sell for SHORT-TERM with Stoploss of 3.30 we also expect STOCK to react on Following IMPORTANT LEVELS. |
MREOSTOCK Price
| Open | 0.25 | Change | Price | % |
| High | 0.30 | 1 Day | -2.02 | -87.45 |
| Low | 0.20 | 1 Week | -1.63 | -84.90 |
| Close | 0.29 | 1 Month | -1.49 | -83.71 |
| Volume | 238479322 | 1 Year | -3.31 | -91.94 |
| 52 Week High 3.86 | 52 Week Low 0.29 | ||||
NASDAQ USA Most Active Stocks
| LPTX | 2.05 | 365.91% |
| AMRS | 0.14 | 100.00% |
| WBA | 11.98 | 0.50% |
| MREO | 0.29 | -87.45% |
| LMDX | 0.02 | 0.00% |
| NVDA | 188.22 | -1.21% |
| YGMZ | 0.02 | -66.67% |
| AKTS | 0.04 | 0.00% |
| LILM | 0.05 | 0.00% |
| PONO | 1.72 | 2.38% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| MREO Daily Charts |
MREO Intraday Charts |
Whats New @ Bazaartrend |
MREO Free Analysis |
|
|
MREO Important Levels Intraday
| RESISTANCE | 0.48 |
| RESISTANCE | 0.42 |
| RESISTANCE | 0.38 |
| RESISTANCE | 0.34 |
| SUPPORT | 0.24 |
| SUPPORT | 0.20 |
| SUPPORT | 0.16 |
| SUPPORT | 0.10 |
MREO Forecast December 2025
| 4th UP Forecast | 2.26 |
| 3rd UP Forecast | 1.63 |
| 2nd UP Forecast | 1.24 |
| 1st UP Forecast | 0.85 |
| 1st DOWN Forecast | -0.27 |
| 2nd DOWN Forecast | -0.66 |
| 3rd DOWN Forecast | -1.05 |
| 4th DOWN Forecast | -1.68 |
MREO Weekly Forecast
| 4th UP Forecast | 1.31 |
| 3rd UP Forecast | 0.98 |
| 2nd UP Forecast | 0.78 |
| 1st UP Forecast | 0.58 |
| 1st DOWN Forecast | 0.00 |
| 2nd DOWN Forecast | -0.20 |
| 3rd DOWN Forecast | -0.40 |
| 4th DOWN Forecast | -0.73 |
MREO Forecast2025
| 4th UP Forecast | 7.5 |
| 3rd UP Forecast | 5.19 |
| 2nd UP Forecast | 3.76 |
| 1st UP Forecast | 2.33 |
| 1st DOWN Forecast | -1.75 |
| 2nd DOWN Forecast | -3.18 |
| 3rd DOWN Forecast | -4.61 |
| 4th DOWN Forecast | -6.92 |
Mereo BioPharma Group plc ( NASDAQ USA Symbol : MREO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
MREO Business Profile
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom. Address: 1 Cavendish Place, London, United Kingdom, W1G 0QF
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service